Duvelisib was the second PI3K inhibitor accepted with the FDA, also based upon a phase III randomized trial.130 The efficacy and safety profile on the drug look similar with People of idelalisib, if not a bit advantageous. Relating to option BTK inhibitors, there are lots of products in improvement, but only acalabrutinib is approved by the FDA wit